The goal of antiviral therapy in patients with chronic hepatitis B is to prevent,through persistent suppression of HBV replication, cirrhosis and hepatocellularcarcinoma. Currently, seven drugs are available: IFN-alpha, pegylated interferon,lamivudine, adefovir dipivoxil, entecavir, telbivudine and tenofovir. The choice of the drugs should always take into consideration the clinical features ofpatients, the antiviral efficacy of each drug, the risk of developing resistance,the long-term safety profile, the method of administration and the cost oftherapy. Ideal candidates for treatment are hepatitis B e antigen-positivepatients with a prolonged phase of immune clearance and hepatitis B eantigen-negative patients with elevated levels of serum HBV DNA, abnormal alanineaminotransferase and histologic evidence of moderate or severe livernecroinflammation and/or fibrosis. Patients with compensated or decompensatedcirrhosis should be treated, even if alanine aminotransferase levels are normaland/or serum HBV DNA levels are low, in order to prevent disease flare and toimprove liver function.
|Numero di pagine||11|
|Rivista||Expert Review of Anti-Infective Therapy|
|Stato di pubblicazione||Published - 2009|
All Science Journal Classification (ASJC) codes